Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 12Leukemia 5Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Hematologic Neoplasms 2Recurrence 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × CPX-351 × Clear all
NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Children's Hospital Medical Center, Cincinnati

Phase 1 Recruiting
21 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡